AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV) In multiple preclinical models ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...

Atopic dermatitis was associated with a significantly increased bipolar disorder risk among a large population-based cohort in the US.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming ...

The prevalence of Meniere disease is higher in people with atopic dermatitis (AD), according to a study published online Nov.

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

Diagnosing and managing feline atopic dermatitis (FAD) can be difficult for clients, and can even be a challenge for ...